Monopar receives Australian ethics clearance to start Phase 1 trial of radiopharmaceutical MNPR-101-Zr

Monopar Therapeutics

HREC clearance in Australia to commence Phase 1 dosimetry trial of MNPR-101-Zr for advanced cancers.
Trial will enroll ~12 patients using PET imaging to assess tumor uptake, biodistribution, and safety.
MNPR-101-Zr is a zirconium-89 labeled version of Monopar's uPAR-targeting antibody; preclinical data showed selective uptake.
If Phase 1 encouraging, Monopar plans to evaluate therapeutic version bound to actinium-225 (Ac-225).
This is Monopar's first human clinical trial using its uPAR targeting agent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.